Open AccessSuccessful determination of nilotinib dosage by therapeutic drug monitoring in a patient with chronic myeloid leukemia developing hepatic dysfunction: A case report
Author(s) -
Nakahara Ryosuke,
Sumimoto Takahiro,
Ogata Masao,
Sato Yuhki,
Itoh Hiroki
Publication year - 2019
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.2191
Subject(s) - nilotinib , medicine , myeloid leukemia , therapeutic drug monitoring , dosing , drug , tyrosine kinase inhibitor , pharmacology , tyrosine kinase , bosutinib , oncology , intensive care medicine , imatinib , cancer , receptor
Fixed dosage regimen is currently the standard therapy with tyrosine kinase inhibitors (TKI). This case report demonstrates successful determination of nilotinib dosage by therapeutic drug monitoring (TDM) in a patient with chronic myeloid leukemia (CML). TDM may provide useful marker for individualized dosing of TKI for the treatment of CML.